Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S270.
doi: 10.21037/atm.2019.12.33.

Antithrombotic therapy after coronary artery stenting in atrial fibrillation: dual therapy encompassing NOAC plus P2Y12 inhibitor is ready for prime time!

Andreas Goette  1
Affiliations
Editorial

Antithrombotic therapy after coronary artery stenting in atrial fibrillation: dual therapy encompassing NOAC plus P2Y12 inhibitor is ready for prime time!

Andreas Goette. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Speaker fees from Abbott, Astra Zeneca, Bayer Health Care, Berlin Chemie, Biotronik, Boehringer Ingelheim, BMS/Pfizer, Boston Scientific, Daiichi-Sankyo, Medtronic, and Omeicos.

Figures

Figure 1
Figure 1
Impact of atrial cardiomyopathy on atrial thrombogenesis in patients with and without AF. In most patients with concomitant risk factors, AF appears to be an epiphenomenon, which characterizes the presence of an atrial cardiomyopathy. The induced endocardial alterations, in particular overexpression of adhesion molecules, cause thrombogenesis in the left atrial appendage. AF, atrial fibrillation.
Figure 2
Figure 2
(A) Summary of the antithrombotic regime in patients with AF and ACS during follow up; (B) summary of the antithrombotic regime in patients with AF and chronic coronary syndrome (CCS, stable coronary artery disease); (C) periprocedural regime of antithrombotic therapy in AF patients undergoing PCI. AF, atrial fibrillation; ACS, acute coronary syndrome; NOAC, non-VKA-antagonist; PCI, percutaneous coronary intervention with stent implantation; DAPT, dual antiplatelet therapy (ASS + P2Y12 inhibitor); ACT, activated clotting time to guide heparin dose; AF dose, NOAC dose per lable to prevent stroke in atrial fibrillation patients.
See this image and copyright information in PMC

Comment on

  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
    Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; AUGUSTUS Investigators. Lopes RD, et al. N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17. N Engl J Med. 2019. PMID: 30883055 Clinical Trial.

References

    1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62. 10.1016/S0140-6736(13)62343-0 - DOI - PubMed
    1. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 2016;18:1455-90. 10.1093/europace/euw161 - DOI - PMC - PubMed
    1. Bukowska A, Lendeckel U, Krohn A, et al. Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney. Europace 2008;10:1212-7. 10.1093/europace/eun206 - DOI - PubMed
    1. Goette A, Jentsch-Ullrich K, Lendeckel U, et al. Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiological role of the atrial natriuretic peptide? Circulation 2003;108:2446-9. 10.1161/01.CIR.0000102968.19341.FC - DOI - PubMed
    1. Merino JL, Lip GYH, Heidbuchel H, et al. Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. Europace 2019;21:1633-8. 10.1093/europace/euz213 - DOI - PMC - PubMed